DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024.
Other News
Acarix AB (publ) publishes Interim Report, April – June 2024
NEW YORK, Aug. 22, 2024 /PRNewswire/ — Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its financial results for the second quarter of 2024. The company achieved record-breaking patch sales and record-breaking gross profit, driven by the success of…
Inari Medical to Present at Upcoming Investor Conferences
IRVINE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences:
Retension Pharmaceuticals Closes $10.4 Million Oversubscribed Series A to Fund Clinical Trials for Patients Suffering from Resistant and Uncontrolled Hypertension
FALLS CHURCH, Va.–(BUSINESS WIRE)–Retension Pharmaceuticals, Inc. is pleased to announce the successful closing of its Series A $10.4 million financing round to initiate a well-powered and controlled Phase 2 clinical study in patients with hypertension uncontrolled on two or more antihypertensives. Inhibition of PDE5 is a long-desired mechanism for enhancing NO-based […]
B-Secur and FIRMINIQ Join Forces to Transform Cardiovascular Health Management
PLANO, Texas & BELFAST, Northern Ireland–(BUSINESS WIRE)–B-Secur, a leader in advanced biosensing technology, and FIRMINIQ, a software product development company specializing in connected health, are proud to announce a strategic partnership aimed at transforming cardiovascular health management globally. “Our new alliance with FIRMINIQ represents a significant leap forward in how we […]
Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress
Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company’s ongoing proof-of-concept (PoC) human clinical trial
Nanox Receives FDA Clearance for HealthCCSng V2.0, Upgraded Version of Advanced AI Cardiac Solution Empowering Physicians in Assessment of Coronary Artery Calcium
HealthCCSng V2.0 introduces additional ‘zero calcium’ categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC detection category output
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
Gosselies (Belgium), August 21, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies to prevent and treat thrombotic and inflammatory diseases, announces today that the DMC reviewed the data from the first 8 patients in a planned review of the ongoing BIRCH Phase 2a trial of BIOX-101 to prevent secondary damage after intracerebral hemorrhagic stroke (ICH).
Adagio Medical Provides Business Updates
August 19, 2024 04:01 PM Eastern Daylight Time LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. “For years there has been underinvestment in and pent-up demand for innovation in ablation […]
Recent
Accelerating Adoption of AI Reporting in Radiology Has Propelled Replacement of Legacy SR Integration Technology
FDA Grants Coredio Breakthrough Designation for AI Platform Bringing Advanced Heart Failure Assessment Beyond the Hospital
BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure
Popular
- No commented posts yet